Schaper Benz & Wise Investment Counsel’s Indivior Pharmaceuticals INDV Stock Holding History

Schaper Benz & Wise Investment Counsel’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Hold	10,003	–	–	0.03%	139
2026 Q1	$305K	Hold	10,003	–	–	0.02%	139
2025 Q4	$359K	Buy	10,003 +3	+0%	+$92	0.03%	137
2025 Q3	$241K	Hold	10,000	–	–	0.02%	146
2025 Q2	$147K	Hold	10,000	–	–	0.01%	152
2025 Q1	$95.3K	Buy	+10,000	New	+$105K	0.01%	149

Other funds holding INDV

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CAM

Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Schaper Benz & Wise Investment Counsel's INDV Position: Q2 2026 in Review

Schaper Benz & Wise Investment Counsel held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 10,003 shares worth $410K. The position accounts for 0.03% of the portfolio, ranked #139.

Schaper Benz & Wise Investment Counsel first reported a position in INDV in Q1 2025 and has held it in 6 quarters since. 59 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Schaper Benz & Wise Investment Counsel held 10,003 shares of Indivior Pharmaceuticals worth $410K as of Q2 2026.
Schaper Benz & Wise Investment Counsel left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
Indivior Pharmaceuticals made up 0.03% of Schaper Benz & Wise Investment Counsel's portfolio in Q2 2026, its #139 holding.
Schaper Benz & Wise Investment Counsel first reported a position in Indivior Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
59 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Schaper Benz & Wise Investment Counsel's 13F filing for Q2 2026, filed 21 Jul 2026.